Literature DB >> 9358559

Glucuronidation of entacapone, nitecapone, tolcapone, and some other nitrocatechols by rat liver microsomes.

P Lautala1, M Kivimaa, H Salomies, E Elovaara, J Taskinen.   

Abstract

PURPOSE: Nitrocatechol COMT inhibitors are a new class of bioactive compounds, for which glucuronidation is the most important metabolic pathway. The objective was to characterize the enzyme kinetics of nitrocatechol glucuronidation to improve the understanding and predicting of the pharmacokinetic behavior of this class of compounds.
METHODS: The glucuronidation kinetics of seven nitrocatechols and 4-nitrophenol, the reference substrate for phenol UDP-glucuronosyltransferase activity, was measured in liver microsomes from creosote-treated rats and determined by non-linear fitting of the experimental data to the Michaelis-Menten equation. A new method that combined densitometric and radioactivity measurement of the glucuronides separated by HPTLC was developed for the quantification.
RESULTS: Apparent K(m) values for the nitrocatechols varied greatly depending on substitution pattern being comparable with 4-nitrophenol (0.11 mM) only in the case of 4-nitrocatechol (0.19 mM). Simple nitrocatechols showed two-fold Vmax values compared with 4-nitrophenol (68.6 nmol min-1 mg-1), while all disubstituted catechols exhibited much lower glucuronidation rate. Vmax/K(m) values were about 10 times higher for monosubstituted catechols compared to disubstituted ones. The kinetic parameters for COMT inhibitors were in the following order: K(m) nitecapone > > entacapone > tolcapone; Vmax nitecapone > entacapone > tolcapone; Vmax/K(m) tolcapone > nitecapone > entacapone.
CONCLUSIONS: Nitrocatechols can in principle be good substrates of UGTs. However, substituents may have a remarkable effect on the enzyme kinetic parameters. The different behaviour of nitecapone compared to the other COMT inhibitors may be due to its hydrophilic 5-substituent. The longer elimination half-life of tolcapone in vivo compared to entacapone could not be explained by glucuronidation kinetics in vitro.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9358559     DOI: 10.1023/a:1012133008134

Source DB:  PubMed          Journal:  Pharm Res        ISSN: 0724-8741            Impact factor:   4.200


  14 in total

1.  Genotoxic effects and chemical compositions of four creosotes.

Authors:  L Nylund; P Heikkilä; M Hämeilä; L Pyy; K Linnainmaa; M Sorsa
Journal:  Mutat Res       Date:  1992-02       Impact factor: 2.433

2.  PLS modelling of structure-activity relationships of catechol O-methyltransferase inhibitors.

Authors:  T Lotta; J Taskinen; R Bäckström; E Nissinen
Journal:  J Comput Aided Mol Des       Date:  1992-06       Impact factor: 3.686

3.  Human liver sulphotransferase and UDP-glucuronosyltransferase: structure-activity relationship for phenolic substrates.

Authors:  A Temellini; M Franchi; L Giuliani; G M Pacifici
Journal:  Xenobiotica       Date:  1991-02       Impact factor: 1.908

4.  Characterization of 1-hydroxypyrene as a novel marker substrate of 3-methylcholanthrene-inducible phenol UDP-glucuronosyltransferase(s).

Authors:  L Luukkanen; E Elovaara; P Lautala; J Taskinen; H Vainio
Journal:  Pharmacol Toxicol       Date:  1997-03

5.  Factors modulating the catalytic specificity of a pure form of UDP-glucuronyltransferase.

Authors:  J Magdalou; Y Hochman; D Zakim
Journal:  J Biol Chem       Date:  1982-11-25       Impact factor: 5.157

6.  Inhibition of soluble catechol-O-methyltransferase and single-dose pharmacokinetics after oral and intravenous administration of entacapone.

Authors:  T Keränen; A Gordin; M Karlsson; K Korpela; P J Pentikäinen; H Rita; E Schultz; L Seppälä; T Wikberg
Journal:  Eur J Clin Pharmacol       Date:  1994       Impact factor: 2.953

7.  Identification of major metabolites of the catechol-O-methyltransferase inhibitor nitecapone in the rat and dog.

Authors:  T Wikberg; J Taskinen
Journal:  Drug Metab Dispos       Date:  1993 Mar-Apr       Impact factor: 3.922

8.  Identification of major metabolites of the catechol-O-methyltransferase inhibitor entacapone in rats and humans.

Authors:  T Wikberg; A Vuorela; P Ottoila; J Taskinen
Journal:  Drug Metab Dispos       Date:  1993 Jan-Feb       Impact factor: 3.922

9.  Pharmacokinetic-pharmacodynamic interaction between the COMT inhibitor tolcapone and single-dose levodopa.

Authors:  J Dingemanse; K Jorga; G Zürcher; M Schmitt; G Sedek; M Da Prada; P Van Brummelen
Journal:  Br J Clin Pharmacol       Date:  1995-09       Impact factor: 4.335

10.  Identification of major urinary metabolites of the catechol-O-methyltransferase inhibitor entacapone in the dog.

Authors:  T Wikberg; P Ottoila; J Taskinen
Journal:  Eur J Drug Metab Pharmacokinet       Date:  1993 Oct-Dec       Impact factor: 2.441

View more
  4 in total

Review 1.  First-pass metabolism via UDP-glucuronosyltransferase: a barrier to oral bioavailability of phenolics.

Authors:  Baojian Wu; Kaustubh Kulkarni; Sumit Basu; Shuxing Zhang; Ming Hu
Journal:  J Pharm Sci       Date:  2011-04-11       Impact factor: 3.534

2.  Structure-Metabolism Relationships in the Glucuronidation of d-Amino Acid Oxidase Inhibitors.

Authors:  Sarah C Zimmermann; Rana Rais; Jesse Alt; Caitlin Burzynski; Barbara S Slusher; Takashi Tsukamoto
Journal:  ACS Med Chem Lett       Date:  2014-10-21       Impact factor: 4.345

3.  Ground- and excited-state stability of the conformers of 3,5-dinitrocatechol and its complexes with W(VI) and V(V): combined theoretical and experimental study.

Authors:  V B Delchev; K B Gavazov; I G Shterev
Journal:  J Mol Model       Date:  2014-12-10       Impact factor: 1.810

4.  Metabolism and disposition of opicapone in the rat and metabolic enzymes phenotyping.

Authors:  Ana I Loureiro; Carlos Fernandes-Lopes; Maria João Bonifácio; Filipa Sousa; László E Kiss; Patricio Soares-da-Silva
Journal:  Pharmacol Res Perspect       Date:  2022-02
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.